Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
celecoxib + paclitaxel
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of celecoxib, a selective COX-2 inhibitor, and paclitaxel, a taxane chemotherapy agent. This combination has been studied for its potential in treating various cancers, particularly non-small cell lung cancer and triple-negative breast cancer. The addition of celecoxib to paclitaxel may enhance antitumor effects through multiple mechanisms, including augmentation of immunogenic cell death and inhibition of prostaglandin synthesis.
02
Targets
MicrotubulePTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on celecoxib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on celecoxib + paclitaxel.